Related Experiment Video
Updated: Mar 10, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Molecular characterization of endometrial cancer and therapeutic implications
Locke Uppendahl1, Sally A Mullany, Boris Winterhoff
1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA.
Purpose Of Review:
This article reviews the emerging comprehensive genomic classification of endometrial carcinoma and discusses the therapeutic implications of these subgroups.
Recent Findings:
Comprehensive, multiplatform evaluation of endometrial cancers by the Cancer Genome Atlas stratified the molecular aberrations into four distinct subtypes: POLE mutations, microsatellite instability, copy-number low/microsatellite stable, and copy-number high/'serous-like.' POLE-mutant tumors have a favorable prognosis and may often be overtreated. Microsatellite instability hypermutated tumors commonly have alterations in the phosphatidylinositide 3-kinases/AKT/mechanistic target of rapamycin pathway and limiting targeted therapy to this group may lead to greater response rates. Copy-number low/microsatellite stable tumors represent the majority of grade 1 and grade 2 endometrioid cancers and have an intermediate prognosis, few TP53 mutations, but frequent mutations in genes involved with Wingless-related integration site signaling. Approximately 25% of high-grade endometrioid tumors have mutational profiles that classify as copy-number high/'serous-like' and might benefit from treatment approaches similar to those for serous tumors.
Summary:
Molecular characterization of endometrial cancer classifies tumors into prognostically significant subtypes with a broad range of therapeutic implications.
Insights
Endometrial cancer is now classified into four genomic subtypes, guiding personalized treatment strategies. Understanding these molecular subgroups, like POLE-mutant and microsatellite instability, improves patient prognosis and therapy selection.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Endometrial carcinoma exhibits significant molecular heterogeneity.
- Accurate classification is crucial for effective treatment strategies.
Purpose of the Study:
- To review the comprehensive genomic classification of endometrial carcinoma.
- To discuss the therapeutic implications of distinct molecular subtypes.
Main Methods:
- Utilized comprehensive, multiplatform genomic evaluation data from The Cancer Genome Atlas (TCGA).
- Stratified endometrial cancers into four molecular subtypes based on genetic aberrations.
Main Results:
- Identified four subtypes: POLE-mutant, microsatellite instability (MSI), copy-number low/microsatellite stable (MSS), and copy-number high/serous-like.
- POLE-mutant tumors show a favorable prognosis; MSI tumors may benefit from targeted therapies.
- Copy-number low/MSS tumors (common in low-grade cancers) have an intermediate prognosis.
- Copy-number high/serous-like tumors (found in high-grade cancers) may respond to serous carcinoma-like treatments.
Conclusions:
- Molecular characterization provides prognostically significant endometrial cancer subtypes.
- Genomic classification offers a framework for tailored therapeutic approaches in endometrial cancer.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
07:46Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
Published on: October 13, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle